Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 121.19 USD -0.02% Market Closed
Market Cap: 150.4B USD

Gilead Sciences Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Gilead Sciences Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$9.9B
CAGR 3-Years
30%
CAGR 5-Years
41%
CAGR 10-Years
-7%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$1.7B
CAGR 3-Years
-52%
CAGR 5-Years
-27%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$8.2B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
1%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Pre-Tax Income
-$31.9m
CAGR 3-Years
70%
CAGR 5-Years
49%
CAGR 10-Years
18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$4.4B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5.1B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Gilead Sciences Inc
Glance View

Gilead Sciences Inc., established in 1987, embarked on its mission with a resolute focus on innovative therapeutic advancements. Nestled in the biotech haven of Foster City, California, Gilead pioneered a path that would see it evolve into a global biopharmaceutical powerhouse. The company’s nucleus is its commitment to discovering, developing, and delivering therapies for diseases with unmet medical needs. Its product portfolio reflects this dedication, notably dominated by groundbreaking advancements in antiviral therapies, particularly for HIV/AIDS, hepatitis B, and hepatitis C. Over the years, its robust research and development engine, fueled by a continual reinvestment of earnings, propelled it to the forefront of tackling complex medical challenges. Its strategic acquisitions, like the pivotal purchase of Pharmasset in 2011, underpinned its ascent in the hepatitis C treatment arena, highlighting its aptitude for identifying and integrating synergistic growth opportunities. Financially, Gilead generates its revenue through the commercialization of its pharmaceutical portfolio. It thrives on a model where its novel therapies, once developed and approved, are sold to healthcare providers and systems. The landscape of antiviral treatments, primarily the revolutionary HIV regimen and hepatitis C cures like Harvoni and Sovaldi, serves as the backbone of its revenue stream. Meanwhile, Gilead's ventures into oncology and inflammatory diseases through strategic acquisitions and partnerships aim to diversify its portfolio beyond infectious diseases. The intricate process from innovation to distribution underscores Gilead’s proficient use of its clinical expertise and market acumen to address both expanding global health needs and shareholder demands, ensuring its enduring presence in the volatile seas of the biotech industry.

GILD Intrinsic Value
119.66 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Gilead Sciences Inc's Pre-Tax Income?
Pre-Tax Income
9.9B USD

Based on the financial report for Sep 30, 2025, Gilead Sciences Inc's Pre-Tax Income amounts to 9.9B USD.

What is Gilead Sciences Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-7%

Over the last year, the Pre-Tax Income growth was 5 517%. The average annual Pre-Tax Income growth rates for Gilead Sciences Inc have been 30% over the past three years , 41% over the past five years , and -7% over the past ten years .

Back to Top